Intuitive Surgical Announces First Quarter Earnings

Intuitive Surgical Announces First Quarter Earnings

SUNNYVALE, Calif., April 22, 2014 (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc.
(Nasdaq:ISRG), the industry leader in surgical robotics, reported revenue
consistent with its April 8, 2014, press release of $465 million for the first
quarter of 2014, a decrease of approximately 24%, compared with $611 million
for the first quarter of 2013.

Revenue reflects a reduction of first quarter of 2014 system revenue by
approximately $24 million as well as instrument and accessory revenue by $2
million associated with a customer trade-out program for the newly launched da
Vinci^® Xi™ Surgical System. Excluding the $26 million deferral relating to
the trade-out program, revenue would have been $491 million, a decrease of
approximately 20% compared with first quarter of 2013.

First quarter 2014 instrument and accessory revenue decreased by approximately
2% to $255 million compared with $261 million for the first quarter of 2013.
The decrease in revenue was driven by lower instrument and accessory stocking
orders associated with lower first quarter 2014 system unit sales and the
revenue deferral of $2 million relating to the da Vinci Xi customer trade-out
program, partially offset by approximately 7% higher da Vinci procedure
volume. Higher procedure volume was driven by growth in U.S. general surgery
procedures and international urologic procedures, partially offset by lower
U.S. gynecologic procedures.

Systems revenue decreased to $106 million in the first quarter of 2014,
compared with $256 million for the first quarter of 2013. The decrease was
driven by lower U.S. systems sales and the revenue deferral of $24 million
relating to the da Vinci Xi customer trade-out program. Intuitive Surgical
shipped 87 da Vinci Surgical Systems during the three months ended March 31,
2014, compared with 164 in the same period last year. The decrease in system
unit shipments primarily reflected lower first quarter of 2014 system sales
into the U.S. market. U.S. system shipments were down in the first quarter of
2014 as a result of lower procedure growth, changing hospital capital-spending
priorities associated with the implementation of the Affordable Care Act, and
the impact that anticipation of a new system may have had on customer
capital-spending decisions.

First quarter of 2014 service revenue increased approximately 10% to $104
million, compared with $94 million for the first quarter of 2013, reflecting
growth in the installed base of da Vinci Surgical Systems.

First quarter of 2014 operating income decreased to $57 million, compared with
$251 million in the first quarter of 2013. Operating results for the first
quarter of 2014 included a pre-tax charge of $67 million related to a probable
loss associated with product liability claims previously announced in the
Company's April 8, 2014 press release.

Intuitive Surgical's income tax rate for the first quarter of 2014 was 26.8%,
compared with 26.1% for the first quarter of 2013.

First quarter 2014 net income, including the $67 million litigation accrual
and reflecting the $26 million revenue deferral associated with the da Vinci
Xi customer trade-out program, was $44 million, or $1.13 per diluted share,
compared with $189 million, or $4.56 per diluted share, for the first quarter
of 2013.

Intuitive Surgical ended the first quarter of 2014 with $3 billion in cash,
cash equivalents and investments, reflecting an increase of $210 million
during the quarter.

Additional supplemental financial and procedure information has been posted to
the Investor Relations section of the Intuitive website at:
http://phx.corporate-ir.net/phoenix.zhtml?c=122359&p=irol-IRHome.

Intuitive Surgical will discuss these results at a conference call today at
1:30 pm PST. The dial-in numbers for the call are (800) 230-1092 for
participants located in the United States and (612) 288-0337 for participants
located outside the United States. The host will be Dr. Gary Guthart, CEO of
Intuitive Surgical. To access financial information that will be discussed on
the call, please visit Intuitive Surgical's website at
www.intuitivesurgical.com.

About Intuitive Surgical, Inc.

Intuitive Surgical, Inc. (Nasdaq:ISRG), headquartered in Sunnyvale, Calif., is
the global leader in robotic-assisted, minimally invasive surgery. Intuitive
Surgical develops, manufactures and markets the da Vinci Surgical System.
Intuitive Surgical's mission is to extend the benefits of minimally invasive
surgery to those patients who can and should benefit from it.

About the da Vinci Surgical System

The da Vinci Surgical System is a surgical platform designed to enable complex
surgery using a minimally invasive approach. The da Vinci Surgical System
consists of an ergonomic surgeon console or consoles, a patient-side cart with
three or four interactive arms, a high-performance vision system and
proprietary EndoWrist® instruments. Powered by state-of-the-art technology,
the da Vinci Surgical System is designed to scale, filter and seamlessly
translate the surgeon's hand movements into more precise movements of the
EndoWrist instruments. The net result is an intuitive interface with improved
surgical capabilities. By providing surgeons with superior visualization,
enhanced dexterity, greater precision and ergonomic comfort, the da Vinci
Surgical System makes it possible for skilled surgeons to perform more
minimally invasive procedures involving complex dissection or reconstruction.
For more information about clinical evidence related to da Vinci Surgery,
please visit www.intuitivesurgical.com/company/clinical-evidence/.

da Vinci® and EndoWrist® are trademarks of Intuitive Surgical, Inc.

INTUITIVE SURGICAL, INC.
UNAUDITED QUARTERLY CONSOLIDATED STATEMENTS OF INCOME
                                                                  
                                             Three months ended
                                             March 31, December 31, March 31,
In millions (except per share data)           2014      2013         2013
Revenue:                                                           
Instruments and accessories                   $254.8  $268.2     $261.1
Systems                                       106.0     204.6        255.9
Services                                      103.9     103.4        94.4
Total revenue                                 464.7     576.2        611.4
Cost of revenue:                                                   
Product                                       113.8     144.2        146.3
Service                                       35.5      34.0         30.8
Total cost of revenue (1)                     149.3     178.2        177.1
Gross profit                                  315.4     398.0        434.3
Operating expenses:                                                
Selling, general, and administrative          215.8     147.7        141.5
Research and development                      43.0      41.7         41.6
Total operating expenses (1)                  258.8     189.4        183.1
Income from operations (2)                    56.6      208.6        251.2
Interest and other income, net                3.9       5.9          4.3
Income before taxes                           60.5      214.5        255.5
Income tax expense                            16.2      48.3         66.6
Net income (3)                                $44.3   $166.2     $188.9
Net income per share:                                              
Basic                                         $1.16   $4.36      $4.69
Diluted (4)                                   $1.13   $4.28      $4.56
Shares used in computing net income per                            
share:
Basic                                         38.3      38.1         40.3
Diluted                                       39.1      38.8         41.4
                                                                  
(1) Includes share-based compensation expense                      
as follows:
Total cost of revenue                         $7.5    $7.6       $6.8
Total operating expenses                      $33.3   $34.0      $31.4
(2) Includes amortization of purchased                             
intangibles as follows:
Income from operations                        $4.7    $4.7       $5.6
(3) Net income includes the effect of the                          
following items:
Deferral of revenue related to Q1'14 trade-in $11.3   $ —        $—
program, net of tax of $8.2
Product liability litigation charge, net of   $48.7   $—         $—
tax of $18.7
(4) Earnings per share include the effect of                       
the following items:
Deferral of revenue related to Q1'14 trade-in $0.29   $—         $—
program, net of tax of $0.21 per share
Product liability litigation charge, net of   $1.25   $—         $—
tax of $0.48 per share


INTUITIVE SURGICAL, INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
                                                        
                                              March 31,  December 31,
In millions                                    2014       2013
Cash, cash equivalents and investments         $2,963.6 $2,753.9
Accounts receivable, net                       239.1      301.4
Inventories                                    185.5      179.6
Property, plant and equipment, net             320.8      309.9
Goodwill                                       147.5      137.4
Deferred tax assets                            166.5      135.7
Other assets                                   171.2      132.4
Total assets                                   $4,194.2 $3,950.3
                                                        
Accounts payable and other accrued liabilities $310.2   $247.2
Deferred revenue                               227.4      201.7
Total liabilities                              537.6      448.9
Stockholders' equity                           3,656.6    3,501.4
Total liabilities and stockholders' equity     $4,194.2 $3,950.3

CONTACT: Investor Relations
         (408) 523-2161
 
Press spacebar to pause and continue. Press esc to stop.